Expression of Leptin Receptor and Effects of Leptin on Papillary Thyroid Carcinoma Cells

作者: Marilena Celano , Valentina Maggisano , Saverio Massimo Lepore , Marialuisa Sponziello , Valeria Pecce

DOI: 10.1155/2019/5031696

关键词:

摘要: Background. Obesity has been hypothesized to contribute the aggressiveness of thyroid cancer through production abnormal levels serum adipokines. Leptin receptor (OB-R) expression also documented in papillary (PTC). Aim. In this translational study, we analyzed vitro effects leptin on growth and migration cells (TPC-1 K1), molecular mechanisms underlying leptin’s action, influence prolonged exposure cell response a protein kinase inhibitor lenvatinib. The OB-R mRNA were investigated vivo series aggressive PTCs divided into two groups based presence BRAF mutation. Results. TPC-1 K1 cells, treatment with (500 ng/ml for 96 h) resulted mild increase proliferation (about 20% over control only ) both lines. Immunoblot analysis revealed slight phosphorylation AKT, but no effect β-catenin phospho-ERK expressions. inhibitory lenvatinib viability lines not influenced by treatment. transcript (in fresh tissues) proteins formalin-fixed paraffin-embedded specimens) expressed all PTC tissues examined, significant differences between BRAF-mutated BRAF-wild-type tumors. Conclusions. These results demonstrate role mildly increasing phenotype without influencing action Further studies will clarify whether it is possible target OB-R, PTCs, as an adjuvant approach these malignancies.

参考文章(26)
Khawla S Al-Kuraya, Abdul K Siraj, Prashant P Bavi, Azhar R Hussain, Shahab Uddin, Omar S Khan, Role of leptin and its receptors in the pathogenesis of thyroid cancer. International Journal of Clinical and Experimental Pathology. ,vol. 4, pp. 637- 643 ,(2011)
Sebastiano Andò, Ines Barone, Cinzia Giordano, Daniela Bonofiglio, Stefania Catalano, The Multifaceted Mechanism of Leptin Signaling within Tumor Microenvironment in Driving Breast Cancer Growth and Progression. Frontiers in Oncology. ,vol. 4, pp. 340- 340 ,(2014) , 10.3389/FONC.2014.00340
Stefania Catalano, Antonella Leggio, Ines Barone, Rosaria De Marco, Luca Gelsomino, Antonella Campana, Rocco Malivindi, Salvatore Panza, Cinzia Giordano, Alessia Liguori, Daniela Bonofiglio, Angelo Liguori, Sebastiano Andò, A novel leptin antagonist peptide inhibits breast cancer growth in vitro and in vivo. Journal of Cellular and Molecular Medicine. ,vol. 19, pp. 1122- 1132 ,(2015) , 10.1111/JCMM.12517
Rebecca E. Schweppe, Joshua P. Klopper, Christopher Korch, Umarani Pugazhenthi, Miriam Benezra, Jeffrey A. Knauf, James A. Fagin, Laura A. Marlow, John A. Copland, Robert C. Smallridge, Bryan R. Haugen, Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. The Journal of Clinical Endocrinology and Metabolism. ,vol. 93, pp. 4331- 4341 ,(2008) , 10.1210/JC.2008-1102
Shih-Ping Cheng, Chin-Wen Chi, Chi-Yuan Tzen, Tsen-Long Yang, Jie-Jen Lee, Tsang-Pai Liu, Chien-Liang Liu, Clinicopathologic significance of leptin and leptin receptor expressions in papillary thyroid carcinoma Surgery. ,vol. 147, pp. 847- 853 ,(2010) , 10.1016/J.SURG.2009.11.004
Efisio Puxeddu, Cosimo Durante, Nicola Avenia, Sebastiano Filetti, Diego Russo, Clinical implications of BRAF mutation in thyroid carcinoma Trends in Endocrinology and Metabolism. ,vol. 19, pp. 138- 145 ,(2008) , 10.1016/J.TEM.2007.12.003
Mingzhao Xing, Recent Advances in Molecular Biology of Thyroid Cancer and Their Clinical Implications Otolaryngologic Clinics of North America. ,vol. 41, pp. 1135- 1146 ,(2008) , 10.1016/J.OTC.2008.07.001
GUO-AN ZHANG, SEN HOU, SHA HAN, JIAN ZHOU, XU WANG, WEN CUI, Clinicopathological implications of leptin and leptin receptor expression in papillary thyroid cancer. Oncology Letters. ,vol. 5, pp. 797- 800 ,(2013) , 10.3892/OL.2013.1125
Osamu Tohyama, Junji Matsui, Kotaro Kodama, Naoko Hata-Sugi, Takayuki Kimura, Kiyoshi Okamoto, Yukinori Minoshima, Masao Iwata, Yasuhiro Funahashi, Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models Journal of Thyroid Research. ,vol. 2014, pp. 638747- 638747 ,(2014) , 10.1155/2014/638747